- Home
- CELC vs PDT Comparison
CELC vs PDT Comparison
Compare CELC & PDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- PDT
- Stock Information
- Founded
- CELC 2011
- PDT 1989
- Country
- CELC United States
- PDT United States
- Employees
- CELC N/A
- PDT N/A
- Industry
- CELC Medical Specialities
- PDT Finance Companies
- Sector
- CELC Health Care
- PDT Finance
- Exchange
- CELC Nasdaq
- PDT Nasdaq
- Market Cap
- CELC 594.7M
- PDT 648.3M
- IPO Year
- CELC 2017
- PDT N/A
- Fundamental
- Price
- CELC $12.66
- PDT $12.69
- Analyst Decision
- CELC Strong Buy
- PDT
- Analyst Count
- CELC 6
- PDT 0
- Target Price
- CELC $29.17
- PDT N/A
- AVG Volume (30 Days)
- CELC 257.7K
- PDT 145.6K
- Earning Date
- CELC 11-14-2024
- PDT 01-01-0001
- Dividend Yield
- CELC N/A
- PDT 8.88%
- EPS Growth
- CELC N/A
- PDT N/A
- EPS
- CELC N/A
- PDT N/A
- Revenue
- CELC N/A
- PDT N/A
- Revenue This Year
- CELC N/A
- PDT N/A
- Revenue Next Year
- CELC N/A
- PDT N/A
- P/E Ratio
- CELC N/A
- PDT N/A
- Revenue Growth
- CELC N/A
- PDT N/A
- 52 Week Low
- CELC $11.51
- PDT $8.77
- 52 Week High
- CELC $22.19
- PDT $13.05
- Technical
- Relative Strength Index (RSI)
- CELC 28.22
- PDT 40.22
- Support Level
- CELC $15.33
- PDT $12.70
- Resistance Level
- CELC $16.14
- PDT $13.24
- Average True Range (ATR)
- CELC 0.97
- PDT 0.23
- MACD
- CELC -0.28
- PDT -0.02
- Stochastic Oscillator
- CELC 22.85
- PDT 16.67
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund II is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest growth of capital. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, and short-term investments.